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Self-assembled palladium and platinum coordination cages: 
Photophysical studies and anticancer activity 
Felix Kaiser,[a] Andrea Schmidt,[a] Wolfgang Heydenreuter,[b] Philipp J. Altmann,[a] Angela Casini,[c] 
Stephan A. Sieber[b] and Fritz E. Kühn[a]* 
 
Abstract: Self-assembled coordination cages are interesting as drug 
delivery systems. Therefore, the synthesis of new M2L4 (M = Pd, Pt) 
molecular cages, derived from highly fluorescent, rigid polyaromatic 
ligands is reported and the first Pt2L4 cage with a ligand consisting of 
three pyridine moieties is described. Photophysical properties were 
examined showing high quantum yields  of up to 48% for the 
methoxy-functionalized ligands. Coordination of the ligands to 
palladium and platinum ions reduces the metallocages’ fluorescence, 
however. The host-guest chemistry of the palladium cages with 
cisplatin is investigated confirming the encapsulation. The cages 
encapsulating cisplatin show a significantly increased cytotoxicity 
towards A549 (human lung adenocarcinoma) cells compared to 
cisplatin, and thus appear to be promising delivery vectors for the 
anticancer drug cisplatin. 
Introduction 
Almost two decades have passed, since McMorran and Steel 
reported the first Pd2L4 molecular cage, capable of enclosing a 
hexafluorophosphate counterion.[1] Since then increasing 
interest on M2L4 complexes with inner cavities has emerged, as 
they are readily accessible through self-assembly by simply 
mixing bidentate ligands and metal precursors. The assemblies 
rely largely on coordinative interactions of Pd2+ and pyridine 
moieties,[2] although some examples with different metal ions, 
such as Pt2+,[3] Co2+,[4] Cu2+,[5] and Zn2+ are known.[3a, 4e] So far 
only a few fluorescent M2L4 cages were obtained using ligands 
with extensive π-systems or attached fluorophores,[3a, 6] although 
highly fluorescent metallocages would be very interesting for 
biological imaging in cells by fluorescence microscopy. Aside 
from fluorescence, the encapsulation of (counter)ions has been 
reported.[4a-d, 5a, 7] Moreover, supramolecular coordination com-
plexes are also capable to encapsulate metal compounds[2b, 6b, 8]  
(e.g. cisplatin) and some of them have been tested concerning 
their cytotoxicity for cancer cells.[8a-e, 9] Cisplatin is one of the 
most widely applied anticancer agent against ovarian, bladder 
and testicular cancer to name just a few.[10] However, its 
effectiveness is accompanied by severe side effects, thus 
limiting the applicable dose.[10b] The necessity to reduce side 
effects and toxicity of cisplatin and its derivatives has gained 
growing appreciation in current research. One possibility is to 
utilize the so called EPR (= enhanced permeability and 
retention) effect, which was discovered in 1986 by Maeda and 
Matsamura.[11] Until now a plethora of vectors for cisplatin has 
been examined, e. g. liposomes,[12] nanoparticles,[13] 
macrocycles,[14] and as already mentioned above, also 
metallocages.[8c, g] Recently, our group evaluated palladium cage 
compounds as drug delivery systems for cisplatin in vitro in 
cancer cells and ex vivo in healthy rat liver tissue.[6e, 8a] Goal of 
this research is to ensure a safe transport of the active 
molecules selectively to the target entity. Solubility, toxicity and 
size of the transporter are of high importance in this context. 
Based on recent results, in this work the synthesis and 
characterization of new M2L4 molecular cages with enhanced 
solubility are described. The photophysical properties of the 
metallocages were investigated, in order to examine the 
possibility of uptake studies in cells. The incorporation of 
electron-donating methoxy groups in the ligand framework could 
potentially increase the photoluminescence of the ligands, thus 
enhancing the emissive properties of the metallocages. 
Moreover, the host guest relationship with cisplatin is examined 
for the palladium cages and the cytotoxicity of the cages and 
their cisplatin inclusion compounds towards human cancer cells 
is examined in vitro.  
Results and discussion 
Rigid bis-monodentate pyridyl ligands 2 and 3, bearing 
functionalizable methoxy moieties were obtained via divergent 
synthesis based on Sonogashira cross coupling reactions 
(Scheme 1). Compound 1 was synthesized in a two-step 
literature procedure.[15] A Sonogashira reaction of 1 with 3,5-
dibromo aniline yielded 2 as a pale yellow solid after flash 
column chromatography. Likewise, reaction of 1 with 2,6-
dibromo pyridine gave ligand 3 as a yellow solid after flash 
column chromatography. The methoxy-functionalization was 
supposed to have increased effects on the solubilty and 
fluorescence properties. Compounds 2 and 3 were 
characterized by 1H, 13C, DOSY NMR, ESI HRMS and IR 
spectroscopy. 
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Scheme 1. Preparation of ligands 2 and 3. Reagents and conditions: i) 3,5-
dibromo aniline, [PdCl2(PPh3)2], CuI, rfx., 3 d, (NEt3); ii) 2,6-dibromo pyridine, 
[PdCl2(PPh3)2], CuI, rfx., 3 d, (NEt3). 
Isostructural M2L4 (M = Pd, Pt) cages 2Pd, 3Pd and 3Pt were 
obtained through self-assembly of the ligands 2 and 3 with 
[Pd(NCCH3)4](BF4)2 or [Pt(NCCH3)2Cl2] and AgClO4, respectively 
(Scheme 2). 
Scheme 2. Synthesis of M2L4 complexes 2Pd, 3Pd and 3Pt via self-assembly in 
acetonitrile. Reagents and conditions: 2Pd and 3Pd: [Pd(NCCH3)4](BF4)2, rfx., 
1 h; 3Pt: [Pt(NCCH3)2Cl2], AgClO4, rfx., 2 d. 
The cages were prepared from a suspension of stoichiometric 
amounts of the starting materials in acetonitrile by heating to 
reflux for one hour (Pd) or two days (Pt). For the platinum cage 
3Pt a purification step via column chromatography was 
necessary. 
Cage formation was validated by 1H, DOSY NMR, ESI HRMS, 
and X-ray structure analysis. In 1H NMR spectra, significant 
shifts are observed, when comparing the cages and the 
corresponding free ligands (Figure 1 and Figure 2).  
As expected, upon coordination the whole signal sets are shifted 
downfield for each complex, especially the signals of Ha and Hb. 
These protons, located in ortho position to the coordinating 
pyridine nitrogen, receive the largest electron withdrawing 
influence of the metal cations (= 0.47 ppm – 0.59 ppm). 
Diffusion-ordered NMR spectroscopy (DOSY) gives additional 
evidence for the formation of M2L4 cages. 
Figure 1. 1H NMR spectra (CD3CN) of 2 and the corresponding molecular 
cage 2Pd. 
Figure 2. 1H NMR spectra (CD3CN) of 3 and the cages 3Pd as well as 3Pt. 
All proton signals of both ligands 2 and 3, and of the complexes 
2Pd, 3Pd, and 3Pt show the same diffusion coefficient (D). 
 The ratio Dligand to Dcomplex is approximately 2:1, which is due to 
the presence of larger cage molecules in solution. Using the 
Einstein-Stokes correlation,[16] the Stokes radii r0 were calculated 
for each cage compound. The values are given in Table 1. 
Table 1. Diffusion coefficients (D) of ligands and M2L4 cage complexes in 
acetonitrile and calculated Stokes radii (r0). 
Component D (10−10 m2·s-1) r0 (Å) 
2 10.7 -- 
2Pd 5.33 11.47 
3 12.2 -- 
3Pd 5.58 10.96 
3Pt 5.60 10.92 
Electrospray ionization high-resolution mass spectra 
(ESI HRMS) provide additional support for the formation of the 
cage complexes. For every cage the signals for the tetra-cationic 
unit [M2L4]4+ (M2+ = Pd2+, Pt2+; L = 2, 3) and its association with 
one or two counterions. [M2L4](X)n(4−n)+ (X− = BF4−, ClO4−) are 
clearly observable (Figure 3, SI). The isotopic distributions fit 
calculated values, which are exemplarily depicted in Figure 4 for 
the fragment [Pt234]4+ in 3Pt. 
European Journal of Inorganic Chemistry 10.1002/ejic.201600811
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Figure 3. ESI HRMS spectrum cutout of 3Pt with the signals for [3+H]+ 
(342.1239), [Pt234]4+ (438.5985), [Pt234](ClO4)3+ (618.1148) and [Pt234](ClO4)22+ 
(977.1459). 
 
Figure 4. ESI HRMS spectrum cutout of 3Pt with the signals that represent the 
isotopic distribution of fragment [Pt234]4+ (top) and the respective calculated 
spectrum (bottom). 
X-ray single crystal structure analysis reveals the formation of 
paddle wheel shaped coordination cages. Single crystals 
suitable for single crystal X-ray diffraction were grown by vapor 
diffusion of diethyl ether into an acetonitrile solution of 2Pd and 
likewise a solution of 3Pd in acetone over several days.  
Cage compound 2Pd crystallizes in the triclinic space group P  
with the inversion center located centrally inside the cavity 
(Figure 5).  
 
Each PdII ion is coordinated in a square-planar fashion by pyridyl 
moieties of four molecules 2 (angles N–Pd–N between 88.6(1)° 
and 90.8(2)°), resulting in a lantern-shaped cage with a central 
cavity. The latter is stocked with disordered solvent molecules, 
not with counterions. The anions are disordered and located 
outside the cage, half of them at the apical position of Pd. These 
observations are in accordance to previously reported results,[8g] 
although numerous examples of M2L4 cage compounds with 
encapsulated counterions exist in literature as well.[1, 6a, 7a, 17] The 
cage diameter, calculated between two opposing methoxy-
moieties is ≈ 22.6 Å (averaged distances between outer 
hydrogen atoms). This fits the value calculated from diffusion 
coefficients (≈ 22.9 Å) well (Table 1). The Pd…Pd distance is 
12.0 Å, diagonally opposing central carbon atoms display an 
averaged distance of 10.5 Å.  
Figure 5. Molecular structure of 2Pd. H, co-crystallized solvent and counterions 
omitted for clarity. Ellipsoids are shown at 50% probability. Element colors: C – 
grey, N – blue, O – red, Pd – turquoise. 
Cage 3Pd also crystallizes in the triclinic space group P  with an 
inversion center located centrally inside the cage (Figure 6). The 
PdII ions are again coordinated in a square-planar fashion to one 
pyridyl moiety of four ligand molecules 3. The resulting lantern-
shaped cage compound exhibits a central cavity that is occupied 
by two non-disordered acetone molecules. The respective 
carbonyl oxygen atoms are pointing to the metal ions with a 
distance of Pd…O of 3.3 Å. The methyl groups are orientated 
towards the ligands’ central pyridine N-atoms with an averaged 
distance C…N of 3.6 Å. As in 2Pd, the BF4− counterions are 
located outside the cage, half of them at the apical position of 
European Journal of Inorganic Chemistry 10.1002/ejic.201600811
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PdII. The cage diameter calculated between two opposing 
methoxy-moieties is ≈ 22.4 Å (averaged distances between 
outer hydrogen atoms), which correlates well with the value 
calculated from diffusion coefficients (≈ 21.9 Å, Table 1). The 
distance between the two Pd atoms is 11.6 Å, diagonally 
opposing central pyridine N display an averaged distance of 
10.9 Å. 
Figure 6. Molecular structure of 3Pd. Thermal ellipsoids are shown at a 50% 
probability level. Side view, drawn with two encapsulated acetone molecules 
(spacefilling representation at 100% of van-der-Waals radii, visualizing the 
steric demand inside the cage; H and counter ions omitted for clarity. Element 
colors: C – grey, N – blue, O – red, Pd – turquoise). 
Complexes 2Pd, 3Pd and 3Pt are soluble in polar solvents like 
DMSO, DMF, acetonitrile and acetone but insoluble in 
chloroform, dichloromethane, pentanes or diethyl ether. They 
are stable in solid state and in solution for weeks. Compound 3Pt 
is slightly sensitive to oxygen and thus has to be stored under an 
argon atmosphere. 
 
The ligands’ and cages’ photophysical properties show a striking 
dependence on the coordination of metal ions, especially 
concerning photoluminescence. The absorption spectra of ligand 
2 and its corresponding cage are depicted in Figure 7. Ligand 2 
displays its strongest absorption bands between 210 and 
320 nm and a weaker band is located between 330 and 370 nm. 
The absorption maximum is observed at 223 nm, with an 
extinction coefficient 223 (2) = 47700 l·mol−1·cm−1. Upon coordi-
nation to PdII a bathochromic shift of 9 nm is observed and 
absorption increases by 3.78 (232 (2Pd) = 180500 l·mol−1·cm−1), 
only differing by 5% from the estimated quadrupling with respect 
to the four molecules 2 per complex 2Pd. 
Figure 7. UV/Vis-spectra of 2 (c = 2  10−5 M, black) and 2Pd (c = 5  10−6 M, 
red) in MeCN, width of cuvette: 10 mm. 
As shown in Figure 8, ligand 3 shows strong absorptions 
between 200 and 330 nm with a local absorption maximum at 
321 nm. It displays an extinction coefficient İ321 (3) = 32500 
l·mol−1·cm−1. Through coordination to PdII or PtII the band 
shapes alter, resulting in formal hypsochromic shifts of the 
maxima (313 nm for PdII and 314 nm for PtII). The extinction 
coefficients rise by factors 4.51 and 3.36, respectively to 
İ313 (3Pd) = 146600 l·mol−1·cm−1 and İ314 (3Pt) = 109300 
l·mol−1·cm−1, differing +13% and −16% from the expected 
quadrupling due to the presence of four ligand molecules per 
cage. Furthermore, upon coordination each a new maximum is 
observed at 230 nm and 229 nm with extinction coefficients of 
İ230 (3Pd) = 171400 l·mol−1·cm−1 and İ229 (3Pt) = 142200 
l·mol−1·cm−1. 
Figure 8. UV/Vis-spectra of 3 (c = 2 · 10−5 M, black), 3Pd (c = 5 · 10−6 M , red) 
and 3Pt (c = 5 · 10−6 M, blue)  in MeCN, width of cuvette: 10 mm. 
While absorption properties of 2 and 3 show a minor influence of 
metal coordination, luminescence is strongly dependent of the 
metal. Excitation of a solution of 2 in acetonitrile with UV light 
leads to a strong emission (290 nm (2) = 42%), with a maximum 
at λem,max (2) = 412 nm. However, coordination to PdII lowers 
significantly the quantum yield (310 nm (2Pd) = 7%), while the 
emission maximum remains almost unaffected λem,max (2Pd) = 
413 nm, Δλem,max = 1 nm), as depicted in Figure 9. 
European Journal of Inorganic Chemistry 10.1002/ejic.201600811
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Figure 9. Luminescence spectra of 2 (2 ∙ 10−5 M, ex = 290 nm) and 2Pd (5 ∙ 
10−6 M, ex = 310 nm) in acetonitrile upon excitation with UV light, intensities 
normalized. 
Ligand 3 shows an even higher quantum yield (300 nm (3) = 
48%), and as intended, the methoxy-functionalization leads to a 
significantly increased fluorescence compared to the unsubsti-
tuted ligand (48% vs. 1.1% ).[6a]   
Analogous to 2, upon coordination of PdII, the quantum yield is 
lowered significantly to 
 300 nm (3Pd) = 3%, the emission 
maximum is bathochromically shifted from λem,max (3) = 345 nm 
to em,max (3Pd) = 352 nm. Platinum cage 3Pt is hardly emissive 
with a quantum yield of less than 0.2%. The emission maximum 
is almost the same as for 3Pd (em,max (3Pd) = 349 nm). The 
emission spectra of all three compounds are shown in Figure 10. 
Unfortunately, uptake studies of the cages in cells by 
fluorescence microscopy could not be performed due to low 
photoluminescence. 
Figure 10. Luminescence spectra in acetonitrile of 3 (2 ∙ 10−5 M, λex = 300 nm), 
3Pd (5 ∙ 10−6 M, λex = 310 nm) and 3Pt (5 ∙ 10−6 M, λex = 310 nm) in acetonitrile 
upon excitation with UV light, intensities normalized. 
 
To examine the encapsulation properties of the palladium cages, 
solutions of 2Pd and 3Pd were treated with distinct amounts of 
cisplatin and analyzed by NMR spectroscopy. Convincing 
evidence for cisplatin encapsulation, both in 2Pd and 3Pd was 
received. Successive addition of 2 and 10 equivalents of 
cisplatin in DMF-d7 to a DMF-d7 solution of 2Pd results in a 
significant broadening of the He signals. These hydrogen atoms 
are pointing directly into the cages inner cavity and thus 
apparently interact with encapsulated cisplatin guest molecules 
(Figure 11). The other signals remain unaffected. This behavior 
is consistent with a similar example reported earlier and was 
described as an indication for the encapsulation of cisplatin.[8a] 
Figure 11. 1H NMR spectrum cutouts (400 MHz, DMF-d7, 296 K) of: a) 2Pd, b) 
2Pd with 2 equiv. cisplatin, c) 2Pd with 10 equiv. cisplatin. 
Addition of 2 equivalents of cisplatin to a CD3CN solution of cage 
3Pd, heating to 60 °C for 10 min and finally ultrasonic treatment 
for 2 min leads to a distinct, macroscopically visible dissolution 
of cisplatin. The 1H NMR spectrum gives also evidence for the 
encapsulation. Primarily the signal from Ha is broadened 
noticeably and furthermore shifted downfield, thus indicating an 
interaction with encapsulated guest molecules (Figure 12). This 
is consistent with similar literature results.[8a, f, g] Alike 
experiments with 3Pt resulted in decomposition products. 
 
Figure 12. 1H NMR spectrum cutouts (400 MHz, CD3CN, 296 K) of: a) 3Pd, b) 
3Pd with 2 equiv. cisplatin. 
The palladium cages 2Pd and 3Pd as well as their respective 
ligands 2 and 3 and the palladium precursor [Pd(NCCH3)4](BF4)2 
were screened for their antiproliferative properties in vitro in 
human cancer cell lines A549 (lung carcinoma) and HepG2 
(hepatocellular carcinoma).[18] The IC50 (inhibitory concentration 
to reduce viability to 50%) values of the compounds were 
determined after 48 hours incubation using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetra-zolium bromide (MTT) 
assay (Table 2). The cage compound 3Pd showed moderate 
cytotoxicity (IC50 = 44-72 µM) in the tested cell lines and is less 
effective compared to cisplatin, while cage 2Pd is non-cytotoxic. 
In contrast, the ligands and the Pd precursor are inactive (IC50 > 
100 µM) in A549 and HepG2. 
Table 2. IC50 values of the compounds [µM] in A549 and HepG2, [(cisplatin)2  
2Pd] and [(cisplatin)2  3Pd], normalized to the concentration of cisplatin. 
 IC50 [µM] (A549) IC50 [µM] (HepG2) 
[Pd(NCCH3)4](BF4)2 > 100 > 100 
2 > 100 > 100 
3 > 100 96.1 ± 1.4 
2Pd > 100 > 100 
3Pd 71.8 ± 9.1 44 ± 11 
cisplatin 16.8 ± 0.7 6.7 ± 0.9 
[(cisplatin)2 2Pd] 11.0 ± 1.3 5.2 ± 0.3 
European Journal of Inorganic Chemistry 10.1002/ejic.201600811
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[(cisplatin)2 3Pd] 6.6 ± 1.0 13.4 ± 3.0 
 
As previously reported,[8a, g] this type of metallocages can poten-
tially function as drug delivery systems due to their ability to 
encapsulate two molecules cisplatin. 1H NMR studies provide 
evidence of the encapsulation of cisplatin within cage 2Pd and 
3Pd (see Figure 11 and Figure 12). The antiproliferative effects of 
the host-guest complexes [(cisplatin)2  2Pd] and [(cisplatin)2  
3Pd] were studied against human carcinoma A549 and HepG2 
(Figure 13). Notably, both host-guest systems show an 
increased cytotoxic effect in A549 compared to cisplatin and the 
cage by itself, while in HepG2 these systems are similar 
effective or even less potent than cisplatin. The low cytotoxicity 
of the cage compounds and the enhanced cytotoxic effect of the 
host-guest systems compared to cisplatin make these 
metallocages attractive candidates as drug delivery systems.  
 
 
Figure 13 IC50 values of Cisplatin and the inclusion compounds [(cisplatin)2  
2Pd] and [(cisplatin)2  3Pd], normalized to the concentration of cisplatin. 
Conclusion 
The synthesis and characterization of new M2L4 (M = Pd, Pt) 
molecular cages 2Pd, 3Pd and 3Pt, starting from rigid, highly 
fluorescent, ligands 2 and 3 is described. The first Pt2L4 cage 
with a rigid tris-pyridine ligand (3) is presented. Additionally, 
absorption and photoluminescence studies of both ligands and 
cages have been performed, showing a lower fluorescence of 
the metallocages in comparison to the highly fluorescent free 
ligands. It could be demonstrated that both 2Pd and 3Pd are 
capable of encapsulating the anticancer drug cisplatin. Notably, 
the palladium precursor and the ligands are non-toxic and the 
palladium cages possess only a low cytotoxicity in cancer cells. 
However, the cage compounds encapsulating cisplatin show an 
increased cytotoxic effect towards human lung cancer cells 
(A549). Thus, the methoxy-functionalized coordination cages are 
promising drug delivery vectors for the anticancer agent cisplatin. 
Further ligand modifications are currently performed in our 
laboratories to increase cage fluorescence. 
Experimental section 
General remarks 
All chemicals were purchased from commercial sources and used 
without further purification, solvents were distilled prior to use. NMR-
spectra were recorded on a Bruker AV 400 or a Bruker AV 400 HD 
spectrometer. IR spectra were collected on a Varian 670 spectrometer. 
ESI HRMS measurements were conducted on a Thermo LTQ FT Ultra. 
UV/Vis spectra were recorded on an Agilent Cary 60. Emission spectra 
and absolute quantum yields were obtained on a Hamamatsu Absolute 
PL QY spectrometer C11347. Compound 1 was synthesized according to 
literature procedures.[15]  
3,5-Bis-((5-methoxypyridin-3-yl)-ethynyl)-aniline (2) 
Compound 1 (1.00 g, 7.76 mmol, 4.00 equiv.), 3,5-dibromoaniline 
(471 mg, 1.88 mmol, 1.00 equiv.), CuI (35.8 mg, 0.19 mmol, 0.10 equiv.) 
and [PdCl2(PPh3)2] (132 mg, 0.19 mmol, 0.10 equiv.) are suspended in 
degassed NEt3 (40 ml) and heated to reflux for three days under an 
argon atmosphere. The suspension is filtered over celite, the filter cake 
washed with CH2Cl2 and the solvent removed under reduced pressure. 
The crude product is purified by flash chromatography (CH2Cl2 : MeOH = 
100 : 0 → 96 : 4). The product 2 is obtained as yellow needles (281 mg, 
791 µmol, 42%). 1H NMR (400 MHz, CD3CN, 296 K): įH (ppm) = 8.31 (d, 
4J = 1.7 Hz, 2H, Ha), 8.27 (d, 4J = 2.9 Hz, 2H, Hb), 7.43 (dd, 4J = 2.9, 1.7 
Hz, 2H, Hc), 7.01 (t, 4J = 1.4 Hz, 1H, He), 6.85 (d, 4J = 1.4 Hz, 2H, Hd), 
4.47 (s, 2H, NH2), 3.87 (s, 6H, Hg). 13C NMR (101 MHz, CD3CN, 297 K): 
įC (ppm) = 156.2, 149.6, 145.0, 138.7, 124.4, 124.1, 122.9, 121.0, 100.9, 
92.3, 86.4, 56.5. DOSY NMR (400 MHz, CD3CN, 298 K): D (m2·s−1) = 
1.07 · 10−9. HRMS (ESI, MeCN): m/z = 356.14 [2+H]+ (calcd. for 
C22H18N3O2+ 356.14), 178.57 [2+2H]2+ (calcd. for C22H19N3O22+ 178.57). 
FTIR (KBr):  (cm−1) = 3323 (br), 3190 (br), 3072 (w), 2934 (w), 2833 (w), 
2211 (w), 1820 (w), 1592 (s), 1454 (m), 1426 (s), 1371 (m), 1314 (m), 
1288 (m), 1243 (m), 1213 (s), 1150 (m), 1108 (w), 1055 (s), 1006 (w), 
912 (m), 858 (s), 699 (s), 581 (m), 534 (m). 
PdII cage [Pd2(2)4](BF4)4 (2Pd) 
A mixture of 2 (32.0 mg, 90.0 µmol, 4.00 eq) and [Pd(NCCH3)4](BF4)2 
(20.0 mg, 45.0 µmol, 2.00 eq) in 9 ml acetonitrile is heated to reflux for 
1 h. After cooling to room temperature, the product is precipitated by 
addition of diethyl ether (60 ml). The solid is filtered off, washed with 
diethyl ether and dried under reduced pressure. 2Pd is obtained as an off-
white solid (30.0 mg, 18.2 µmol, 81%). 1H NMR (400 MHz, CD3CN, 297 
K): įH (ppm) = 8.90 (d, 4J = 1.4 Hz, 8H, Ha), 8.79 (d, 4J = 2.6 Hz, 8H, Hb), 
7.64 (dd, 4J = 2.6, 1.4 Hz, 8H, Hc), 7.18 (t, 4J = 1.4 Hz, 4H, He), 6.88 (d, 
4J = 1.4 Hz, 8H, Hd), 4.57 (s, 8H, NH2), 3.95 (s, 24H, Hg). 13C NMR (101 
MHz, CD3CN, 293 K): įC (ppm) = 158.4, 149.8, 145.6, 139.0, 128.0, 
124.6, 124.0, 123.5, 119.2, 95.3, 84.0, 57.7. DOSY NMR (CD3CN, 400 
MHz, 298 K): D (m2·s−1) = 5.33 · 10−10. HRMS (ESI, MeCN): m/z = 
408.33 [(2Pd − 4 BF4−)4+] (calcd. for C88H68N12O8Pd24+ 408.08), 574.11 
[(2Pd – 3 BF4−)3+] (calcd. for C88H68BF4N12O8Pd23+ 573.11), 903.67 [(2Pd − 
2 BF4−)2+] (calcd. for C88H68B2F8N12O8Pd22+ 903.17). FTIR (KBr):  
(cm−1) = 3458 (br), 3387 (br), 3087 (m), 2948 (w), 2220 (m), 1588 (s), 
1461 (m), 1427 (m), 1317 (m), 1259 (w), 1222 (m), 1155 (m), 1053 (s), 
875 (m), 691 (m), 581 (w), 414 (s). 
2,6-Bis-((5-methoxypyridin-3-yl)-ethynyl)-pyridine (3) 
3-Ethynyl-5-methoxy pyridine (787 mg, 5.91 mmol, 4.00 eq), 2,6-
dibromopyridine (350 mg, 1.48 mmol, 1.00 eq), CuI (28.1 mg, 148 µmol, 
0.10 eq) and [PdCl2(PPh3)2] (104 mg, 148 µmol, 0.10 eq) are suspended 
in degassed NEt3 (27 ml) and heated to reflux for three days under an 
argon atmosphere. The suspension is filtered over celite, the filter cake 
washed with CH2Cl2 and the solvent removed under reduced pressure. 
The crude product is purified by flash chromatography (CH2Cl2 : MeOH = 
99 : 1 → 96 : 4) and product 3 obtained as an off-white solid (420 mg, 
1.23 mmol, 83%). 1H NMR (400 MHz, CD3CN, 296 K): įH (ppm) = 8.40 (d, 
4J = 1.6 Hz, 2H, Ha), 8.32 (d, 4J = 2.9 Hz, 2H, Hb), 7.86 (t, 3J = 7.8 Hz, 1H, 
Hf), 7.62 (d, 3J = 7.8 Hz, 2H, Hd), 7.39 (dd, 4J = 2.9, 1.6 Hz, 2H, Hc), 3.88 
(s, 6H, Hg). 13C NMR (101 MHz, CDCl3, 293 K): įC (ppm) = 155.2, 144.9, 
HepG2 A549 
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143.4, 138.6, 136.9, 126.9, 122.7, 119.5, 90.9, 86.4, 55.8. DOSY NMR 
(CD3CN, 400 MHz, 298 K): D (m2·s−1) = 1.22 · 10−9. HRMS (ESI, MeCN): 
m/z = 342.12 [(3+H)+] (calcd. for C21H16N3O2+ 342.12), 171.57 [(3+2H)2+] 
(calcd. for C21H17N3O22+ 171.57). FTIR (KBr):  (cm−1) = 3438 (br), 3046 
(w), 2983 (w), 2946 (w), 2219 (w), 1582 (s), 1454 (s), 1417 (s), 1313 (w), 
1256 (s), 1223 (s), 1166 (m), 1038 (s), 1013 (m), 947 (m), 908 (w), 875 
(m), 805 (m), 747 (w), 700 (m), 671 (m), 585 (w), 545 (m), 410 (s). 
PdII cage [Pd2(3)4](BF4)4 (3Pd) 
A mixture of 3 (14.3 mg, 41.9 µmol, 4.00 eq) and [Pd(NCCH3)4](BF4)2 
(9.30 mg, 21.0 µmol, 2.00 eq) in 10 ml MeCN is heated to reflux for 1 h 
and the product precipitated by addition of diethyl ether (80 ml) after 
cooling to 4 °C. The solid is centrifuged off, washed with diethyl ether 
(10 ml) and dried in vacuo. 3Pd is obtained as an off-white solid (20.2 mg, 
10.5 µmol, 100%). 1H NMR (400 MHz, CD3CN, 297 K): įH (ppm) = 8.92 
(d, 4J = 1.4 Hz, 8H, Ha), 8.82 (d, 4J = 2.6 Hz, 8H, Hb), 7.88 (dd, 4J = 8.2, 
7.5 Hz, 4H, Hf), 7.74 (dd, 4J = 2.6, 1.4 Hz, 8H, Hc), 7.66 (d, 4J = 7.8 Hz, 
8H, Hd), 3.97 (s, 24H, Hg). 13C NMR (101 MHz, CD3CN, 297 K): įC (ppm) 
= 158.5, 146.0, 143.3, 139.8, 138.7, 129.4, 128.7, 123.7, 94.1, 83.3, 57.8. 
DOSY NMR (CD3CN, 400 MHz, 298 K): D (m2·s−1) = 5.58 · 10−10. HRMS 
(ESI, MeCN): m/z = 394.32 [(3Pd − 4 BF4−)4+] (calcd. for 
C84H60N12O8Pd24+ 394.07), 555.43 [(3Pd − 3 BF4−)3+] (calcd. for 
C84H60BF4N12O8Pd23+ 554.42), 874.64 [(3Pd − 2 BF4−)2+] (calcd. for 
C84H60B2F8N12O8Pd22+ 875.14). FTIR (KBr):  (cm−1) = 3430 (br), 3088 
(m), 2947 (w), 2850 (w), 2224 (w), 1813 (w), 1587 (s), 1456 (s), 1336 (s), 
1248 (s), 1150 (s), 1055 (s), 876 (m), 809 (m), 731 (w), 691 (m), 589 (w), 
532 (w), 419 (w). 
PtII cage [Pt2(3)4](ClO4)4 (3Pt) 
A mixture of 3 (25.4 mg, 74.3 µmol, 4.00 eq), [PtCl2(NCCH3)2] (12.9 mg, 
37.1 µmol, 2.00 eq) and AgClO4 (15.4 mg, 74.3 µmol, 4.00 eq) is 
dispersed in 3 ml acetonitrile and heated to reflux for 2 days in the dark. 
The dispersion is filtered, the product precipitated by addition of diethyl 
ether (30 ml) and centrifuged. The crude product is dissolved in 
acetonitrile, filtered over silica and the silica washed with acetonitrile 
(20 ml). The product is eluted from silica with a mixture of 
acetone : methanol : water : KNO3(aq) (sat.) = 24 : 12 : 3 : 1. The organic 
solvents are evaporated under reduced pressure, the solid centrifuged off, 
dissolved in acetonitrile and filtered. After addition of 1 mL sat. aqueous 
LiClO4 the organic solvents are evaporated under reduced pressure, the 
product centrifuged off the resulting dispersion, washed with water (2 × 
10 ml), ethanol (2 ml) and diethyl ether (10 mL) and dried in vacuo. 3Pt is 
obtained as a pale brown solid (8.00 mg, 3.72 µmol, 20%). 1H NMR (400 
MHz, CD3CN, 296 K): įH (ppm) = 8.87 (d, 4J = 1.5 Hz, 8H, Ha), 8.84 (d, 4J 
= 2.6 Hz, 8H, Hb), 7.88 (dd, 3J = 8.2, 7.4 Hz, 4H, Hf), 7.73 (dd, 4J = 2.6, 
1.5, 8H, Hc), 7.67 (d, 3J = 7.8 Hz, 8H, Hd), 3.98 (s, 24H, Hg). 13C NMR 
(101 MHz, CD3CN, 293 K): įC (ppm) = 158.8, 147.0, 143.3, 140.9, 138.7, 
129.4, 129.1, 123.9, 94.0, 83.1, 58.0. DOSY NMR (CD3CN, 400 MHz, 
298 K): D (m2·s−1) = 5.60 · 10−10. HRMS (ESI, MeCN): m/z = 438.60 [(3Pt 
− 4 ClO4−)4+] (calcd. for C84H60N12O8Pt24+ 438.60), 618.11 [(3Pt − 3 
ClO4−)3+] (calcd. for C84H60ClN12O12Pt23+ 618.11), 977.15 [(3Pt − 2 
ClO4−)2+] (calcd. for C84H60Cl2N12O16Pt22+ 977.15). FTIR (ATR):  (cm−1) 
= 3084 (w), 2158 (w), 1585 (m), 1456 (m), 1425 (w), 1334 (w), 1315 (w), 
1248 (w), 1234 (w), 1092 (vs), 1014 (w), 984 (w), 876 (m), 810 (w), 690 
(m), 623 (s). 
MTT cytotoxicity assay standard procedure: 
This essay was performed in 96 well plates. A549/HepG2 cells were 
grown to 30-40 % confluence. The medium was removed and 100 µL 
medium /well containing 1 µL DMF compound stock were added to the 
cells and incubated for 48 h. All concentrations as well as a DMF control 
were tested in technical triplicates and biological duplicates. 20 µL 
Thiazolyl Blue Tetrazolium bromide (5 mg/mL in PBS, Sigma Aldrich) 
were added to the cells and incubated for 2-4 h until complete 
consumption was observed. After removal of the medium, the resulting 
formazan was dissolved in 200 µL DMSO. Optical density was measured 
at 570 nm (562 nm) and background subtracted at 630 nm (620 nm) by a 
TECAN Infinite® M200 Pro. For calculation of IC50 values, residual 
viabilities for the respective compound concentration were fitted to 
viability [%], inhibitor concentration [µM] and Hill slope using Graphpad 
Prism 6.0. 
Crystallographic details 
Additional details of the crystallographic measurements can be found in 
the Supporting Information. CCDC numbers: 1453095-1453096. 
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New non-toxic, self-assembled M2L4 
coordination cages are synthesized 
from highly fluorescent ligands. The 
cages are able to encapsulate the 
anticancer drug cisplatin and 
enhance its cytotoxicity towards 
cancer cells. 
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